Archives
In Situ Electroporation and Impedance Monitoring
2026-10-07
A 2026 Scientific Reports study presents in situ electroporation as a localized approach for delivering DNA, mRNA, siRNA, and aptamers into adherent mammalian cells. By pairing delivery with impedance-based monitoring, the authors connect membrane perturbation, recovery, nucleic-acid activity, and later cell-death phenotypes within a single analytical framework.
FPH1 (BRD-6125): Evidence and Research Context
2026-10-07
FPH1 (BRD-6125) is a vendor-described small molecule intended to support functional proliferation in primary human hepatocytes. The supplied product dossier associates it with increased albumin secretion, higher CYP3A4, lower AFP, and concentration-dependent increases in hepatocyte nuclei and mitotic activity. These findings should be interpreted separately from the 2026 light-inducible RNA-releasing protein study, which concerns translational gene control rather than FPH1 biology.
α-Bungarotoxin and Cholinergic Signaling Research
2026-10-06
A source-grounded overview of α-Bungarotoxin as a nicotinic receptor blockade tool, with emphasis on α7 nicotinic acetylcholine receptor research, the reported preeclampsia-model findings, evidence strength, and important applicability limits.
Phosphatase Inhibitor Cocktail 1: Research Context
2026-10-06
A source-grounded overview of Phosphatase Inhibitor Cocktail 1, its conceptual role in protein phosphorylation preservation, and its relevance to interpreting the IL-34–macrophage mechanism reported in p53-inactivated liver cancer.
Catalpol and Cardio-Cerebrovascular Protection
2026-10-05
This review synthesizes evidence that catalpol may protect the heart and cerebrovascular system through antioxidant, anti-inflammatory, anti-apoptotic, and mitochondrial mechanisms. Its main value is integrative: it connects disease models, molecular signaling pathways, pharmacokinetic considerations, and safety questions while emphasizing that clinical evidence remains limited.
Dabigatran and Thrombin-Centered CVD Research
2026-10-05
Dabigatran offers a precise lens for studying thrombin biology, while catalpol research highlights the broader inflammatory and oxidative dimensions of cardio-cerebrovascular disease. This evidence-focused guide connects target engagement, assay interpretation, and translational limits without reducing complex CVD biology to a single pathway.
Doxorubicin Hydrochloride: Research Context and Evidence
2026-10-04
Doxorubicin hydrochloride, also known as Adriamycin HCl, is widely studied in cancer biology, delivery science, and cardiotoxicity research. This overview separates established research uses from supplier claims, examines findings from a 2025 dual-loaded liposome methods study, and explains why analytical performance, cellular effects, animal outcomes, and clinical relevance should not be treated as interchangeable evidence.
TRIM21–ERK1/2 Signaling in Pituitary Adenomas
2026-10-03
A 2025 Neuro-Oncology study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and dopamine-agonist resistance. Its integrated genetic, proteomic, biochemical, and pharmacological evidence nominates TRIM21 and Quisinostat-associated pathway modulation as research leads, while leaving clinical translation and target specificity unresolved.
Estrogen Receptor–Autophagy Axis in Perimenopause
2026-10-02
This study integrates NHANES cohort data, a perimenopausal mouse model, network pharmacology, and inhibitor-based validation to examine how declining estradiol relates to cardiometabolic disease and multi-organ fibrosis. Its central contribution is evidence that receptor-dependent autophagy, including mTOR-regulated signaling, links estrogen exposure with structural protection of the heart, aorta, and kidneys.
Bafilomycin C1 in High-Content Cell Assays
2026-10-01
Bafilomycin C1 provides a mechanistic way to perturb V-ATPase-dependent lysosomal acidification while high-content imaging captures broader cellular phenotypes. This article translates that principle into autophagy, apoptosis research, and iPSC-cardiomyocyte screening workflows with practical controls and troubleshooting guidance.
Enzyme-Induced Hypoxia and Urothelial Inflammation
2026-10-01
Hudson and colleagues show that hypoxia duration separates an early urothelial stress response from later caspase-1-associated inflammation. Their enzyme-induced hypoxia model links prolonged exposure to a ROS–TXNIP–NLRP3 mechanism and provides a useful framework for interpreting verapamil as a pathway perturbation rather than a selective inflammasome probe.
Standardized Whole-Blood Stimulation and Immunometabolism
2026-09-30
Zhao and colleagues present a standardized whole-blood stimulation protocol for examining how metabolic interventions reshape cytokine responses to innate immune and microbial stimuli. Its main contribution is methodological: by preserving the human blood environment while controlling stimulation, metabolic modulation, controls, and cytokine measurement, the workflow supports reproducible cohort-level immunometabolism studies.
Vernakalant for Rapid Atrial Fibrillation Conversion
2026-09-30
This phase 3 randomized trial evaluated vernakalant hydrochloride as a rapid pharmacological strategy for converting atrial fibrillation to sinus rhythm. Its main contribution was evidence that an atrium-focused, early-activating potassium and frequency-dependent sodium channel blocker could terminate recent-onset atrial fibrillation within minutes, although safety monitoring and patient selection remain important.
Saracatinib (AZD0530) Experimental Workflow
2026-09-29
Build reproducible Src/Abl kinase experiments with Saracatinib (AZD0530), from concentration selection and migration assays to pathway-level validation. The workflow also explains how findings on Reelin–SFK signaling can guide careful, hypothesis-driven extensions into synaptic research without overstating cross-domain evidence.
Trifluoperazine 2HCl: Assay Workflows
2026-09-29
Build reproducible dopamine D2 receptor, macrophage ROS/autophagy, and cancer-screening assays with Trifluoperazine 2HCl. This practical guide combines concentration design, fresh-stock handling, orthogonal controls, and lessons from a structurally distinct PDK4 inhibitor study.
612 records 6/41 page Previous Next First page 上5页 678910 下5页 Last page